Comparison of 18F-FDG and 18F-FDHT Uptake in Patients with Advanced, Progressing Prostate Cancer
Patient no. | Therapy* | Total no. of lesions | 18F-FDHT | 18F-FDG | ||||
---|---|---|---|---|---|---|---|---|
No. of positive lesions | SUV | No. of positive lesions | SUV | |||||
1 | Leuprolide,† 17-AAG‡ | 7 | 3 | 5.70 | 7 | 7.40 | ||
2 | Leuprolide† | 9 | 5 | 3.45 | 9 | 4.70 | ||
3 | Goserelin,† testosterone‡ | 16 | 15 | 4.73 | 16 | 4.56 | ||
4 | Leuprolide† | 4 | 4 | 3.30 | 4 | 4.63 | ||
5 | Orchiectomy† | 9 | 7 | 2.98 | 9 | 4.12 | ||
Oral cyclophosphamide† | ||||||||
Pamidronate† | ||||||||
Celecoxib† | ||||||||
6 | Leuprolide,† testosterone‡ | 6 | 4 | 6.53 | 4 | 4.05 | ||
7 | Goserelin† | 8 | 8 | 10.28 | 8 | 7.08 | ||
Total | 59 | 46 (77%) | 5.28§ | 57 (97%) | 5.22§ |
↵* The generic name, trade name, manufacturer, and description are as follows: leuprolide (Lupron; TAP Pharmaceuticals USA), gonadotropin-releasing hormone analog; goserelin (Zoladex; Zeneca USA), gonadotropin-releasing hormone analog; cyclophosphamide (Cytoxan; Bristol MeyersSquibb USA), antineoplastic; pamidronate (Aredia; Novartis USA), bisphosphonate; celecoxib (Celebrex; Searle), nonsteroidal antiinflammatory.
↵† Baseline scan.
↵‡ Follow-up scan.
↵§ Mean.